Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Noble

Showing results (511-520 of 568) with videos related to

Pageof 57
Sort By:
Emerging Infectious Diseases|January 26, 2021
Outbreak of Severe Vomiting in Dogs Associated with a Canine Enteric Coronavirus, United KingdomAlan D Radford, David A Singleton, Chris Jewell, et al.
Chemistry & Biology|September 1, 2015
Identification and Characterization of an Irreversible Inhibitor of CDK2Elizabeth Anscombe, Elisa Meschini, Regina Mora-Vidal, et al.
Organic & Biomolecular Chemistry|June 16, 2007
Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2Francesco Marchetti, Kerry L Sayle, Johanne Bentley, et al.
Science (New York, N.Y.)|August 3, 2023
Peptide YY: A Paneth cell antimicrobial peptide that maintains <i>Candida</i> gut commensalismJoseph F Pierre, Brian M Peters, Diana La Torre, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2011
MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinonesAnna F Watson, Junfeng Liu, Karim Bennaceur, et al.
Brain Communications|July 6, 2026
Inflammatory alterations mediate tau-associated neurodegenerationPatrick J Lao, Seonjoo Lee, Daniel Talmasov, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2Kerry L Sayle, Johanne Bentley, F Thomas Boyle, et al.
BMJ (Clinical Research Ed.)|October 31, 2022
Clinical and cost effectiveness of single stage compared with two stage revision for hip prosthetic joint infection (INFORM): pragmatic, parallel group, open label, randomised controlled trialAshley W Blom, Erik Lenguerrand, Simon Strange, et al.
Journal of Medicinal Chemistry|December 23, 2025
Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current TherapiesHannah L Stewart, Cinzia Bordoni, Claire E Jennings, et al.
Journal of Medicinal Chemistry|July 26, 2002
Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivativesAshleigh E Gibson, Christine E Arris, Johanne Bentley, et al.
Pageof 57

Showing results (511-520 of 568) with videos related to

Sort By:
Pageof 57
Emerging Infectious Diseases|January 26, 2021
Outbreak of Severe Vomiting in Dogs Associated with a Canine Enteric Coronavirus, United KingdomAlan D Radford, David A Singleton, Chris Jewell, et al.
Chemistry & Biology|September 1, 2015
Identification and Characterization of an Irreversible Inhibitor of CDK2Elizabeth Anscombe, Elisa Meschini, Regina Mora-Vidal, et al.
Organic & Biomolecular Chemistry|June 16, 2007
Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2Francesco Marchetti, Kerry L Sayle, Johanne Bentley, et al.
Science (New York, N.Y.)|August 3, 2023
Peptide YY: A Paneth cell antimicrobial peptide that maintains <i>Candida</i> gut commensalismJoseph F Pierre, Brian M Peters, Diana La Torre, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2011
MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinonesAnna F Watson, Junfeng Liu, Karim Bennaceur, et al.
Brain Communications|July 6, 2026
Inflammatory alterations mediate tau-associated neurodegenerationPatrick J Lao, Seonjoo Lee, Daniel Talmasov, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2Kerry L Sayle, Johanne Bentley, F Thomas Boyle, et al.
BMJ (Clinical Research Ed.)|October 31, 2022
Clinical and cost effectiveness of single stage compared with two stage revision for hip prosthetic joint infection (INFORM): pragmatic, parallel group, open label, randomised controlled trialAshley W Blom, Erik Lenguerrand, Simon Strange, et al.
Journal of Medicinal Chemistry|December 23, 2025
Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current TherapiesHannah L Stewart, Cinzia Bordoni, Claire E Jennings, et al.
Journal of Medicinal Chemistry|July 26, 2002
Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivativesAshleigh E Gibson, Christine E Arris, Johanne Bentley, et al.
Pageof 57